Belimumab

• Clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemi… Pending
  2024-517753-27-01 Phase III 1 country Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. E…
• Belimumab CTD-ILD - Long Term Extension/Follow up to pivotal studies BLISSc-ILD and BEconneCTD-ILD Recruiting
  2023-509370-39-00 Phase III 8 countries Glaxosmithkline Research & Development Limited
• A study of the efficacy and safety of Belimumab in adults with interstitial lung disease associated with connective tissue disease. Recruiting
  2024-513018-36-00 Phase III 7 countries Glaxosmithkline Research & Development Limited
• Belimumab in SLE Recruiting
  2024-518966-28-00 Phase IV 1 country Amsterdam UMC Stichting
• BE-MOBILYZED: BElimumab to MOBIlise memory B-cells from secondary LYmhoid organs to improve memory B-cell HLA-specificity profiling to suppo… Recruiting
  2023-508116-32-00 Phase II 1 country Academisch Ziekenhuis Leiden
• A study describing the efficacy and safety of belimumab administered subcutaneously in adult participants with early systemic lupus erythema… Recruiting
  2023-509146-35-00 Phase IV 6 countries Glaxosmithkline Research & Development Limited
• A clinical trial to learn about the effects of YTB in people with difficult to treat active systemic lupus erythematosus (SLE), or active k… Recruiting
  2023-510150-17-00 Phase II 13 countries Novartis Pharma AG
• A study of the efficacy and safety of belimumab compared to placebo in adults with systemic sclerosis-associated interstitial lung disease. Recruiting
  2023-503219-14-01 Phase II/III 8 countries Glaxosmithkline Research & Development Limited
• TRIBECA - Multicenter randomized double-blind study comparing the efficacy and safety of belimumab in the treatment of non-infectious active… Recruiting
  2024-516237-12-00 Phase II 1 country Assistance Publique Hopitaux De Paris
• A randomized trial to investigate the reset of humoral autoimmunity by combining belimumab with rituximab in severe systemic lupus erythemat… Recruiting
  2023-507867-20-00 Phase II/III 1 country Academisch Ziekenhuis Leiden
• RITUX-PLUS 2 : A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of rituximab combined with subcutane… Ended
  2024-516168-27-00 Phase III 1 country Assistance Publique Hopitaux De Paris
• A phase II trial of belimumab in combination with rituximab/venetoclax in patients with refractory or relapsed chronic lymphocytic leukemia Ended
  2024-511474-68-00 Phase II 1 country Universitaetsklinikum Tuebingen AöR
• A study of belimumab in children with systemic lupus erythematosus (SLE) Ended
  2023-509413-37-00 Phase II 2 countries Glaxosmithkline Research & Development Limited
• Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy (PLUTO) Ended
  2024-512730-15-00 Phase II 1 country Glaxosmithkline Research & Development Limited

Showing 1–14 of 14 trials